The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination
Patients that do not qualify for one of the histologic cohorts may be considered for registration in the Not Otherwise Categorized Rare Tumors cohort with confirmation of at least one of the study chairs via email
Patients must have slides available for submission to central pathology review; this review is mandatory prior to registration to confirm eligibility and proper cohort assignment\r\n* HISTOLOGIC COHORT : Undifferentiated pleomorphic sarcoma (includes: malignant fibrous histiocytoma, myxofibrosarcoma, high grade sarcoma not otherwise specified [NOS])\r\n* HISTOLOGIC COHORT : Leiomyosarcoma (either uterine or extra-uterine)\r\n* HISTOLOGIC COHORT : Other (either malignant peripheral nerve sheath tumor or synovial sarcoma); during the phase II portion of the study, enrollment will be limited to maximum of  patients in this cohort\r\n** Note that the phase I is limited to the histologic subtypes listed above; since patients will be enrolling onto dose cohorts during the phase I, they will not enroll onto specific histologic cohorts, although the histologic subtype informed will be collected during patient enrollment
Newly diagnosed patients must have histologic verification of a primary extracranial germ cell tumor in any of the categories outlined; elevation of serum tumor markers without histologic confirmation is not sufficient for entry on the trial\r\n* NOTE: for low risk patients, materials for rapid surgical central review must be sent within  days of study enrollment
Histologic documentation of invasive adenocarcinoma of the breast
Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least  lesion accessible for biopsy
Subjects must have histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).; acquisition of existing formalin fixed paraffin embedded (FFPE) tumor tissue by study investigators is not mandatory for enrolment on the trial; patients without previous histologic/cytologic confirmation must have freshly obtained biopsy for routine pathologic evaluation before enrolment on the study
There must be histologic confirmation of a diagnosis of colorectal adenocarcinoma.
Histologic or cytologic diagnosis of cancer
Patients must have radiologic evidence of recurrent, refractory or progressive malignant central nervous system (WHO grade III or IV) or solid tumor; for patients with radiologic features of DIPG histologic confirmation of diagnosis is not required though biopsy is suggested if clinically indicated
Histologic confirmation of original prostate cancer diagnosis per institutional standard; life expectancy of greater than  months
Histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable), with measurable disease per RECIST v.
Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least  lesion accessible for biopsy
Surgical and pathology reports that document surgery was limited to biopsy and histologic confirmation.
histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable)
For Pha monotherapy and combination cohorts, histologic or cytologic confirmation of advanced solid tumor.
Histologic or cytologic diagnosis of a WDNET, Ki =< %, unresectable, of foregut origin (thymic, bronchopulmonary, gastric, duodenal, and pancreatic) confirmed by the enrolling institution\r\n* Note: If patients have a functional NET, they are permitted to continue on a somatostatin analog for hormonal symptom control
Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v.
Subject has histologic or cytologic confirmation of metastatic NSCLC. Subjects must have a TPS score available as determined by an FDA approved test. Subject has stable disease or disease progression and is being treated with pembrolizumab therapy as standard of care by the Investigator.
Confirmed unresectable or metastatic hepatocellular carcinoma; confirmation either by histologic confirmation or accepted radiographic criteria
Histologic proof or unequivocal cytologic proof of solid tumor malignancy; this may be obtained from either the primary or any metastatic site
Subjects must have a histologic diagnosis of urothelial carcinoma with radiologic, histologic or cytologic evidence of metastatic disease
Histologic diagnosis of Richters syndrome (RS)
All patients must have histologic proof of solid tumor malignancy and radiographic evidence of spine metastasis
Histologic diagnosis of GIST
An interval of at least  weeks from the completion of radiation therapy to registration unless there is unequivocal histologic confirmation of tumor progression
Subjects must have a histologic diagnosis of clear cell renal cell carcinoma (pure or mixed) with radiologic or histologic or cytologic evidence of metastatic disease
Histologic, cytologic, or radiologically evidence of locally advanced, residual, or recurrent solid malignancy of the abdomen or pelvis requiring surgical resection
Patients must have histologic or radiographic proof of a primary liver malignancy suitable for radiation therapy
Histologic confirmation of malignancy
Histologic or cytologic confirmation of advanced solid tumor.
Histologic or cytologic diagnosis of adenocarcinoma of the pancreas
Must have histologic or cytologic confirmation of recurrent metastatic pancreatic adenocarcinoma based on standard diagnostic criteria. Recurrence must be documented by diagnostic biopsy.
Histologic evidence of muscularis propria invasion
Have a histologic or cytologic diagnosis of stage IV NSCLC
No histologic documentation of EOC
Cytologic or histologic proof of adenocarcinoma of the pancreas; patients can have tumor which is locally advanced or borderline resectable; unequivocal metastases and islet cell tumors are not eligible
Patients must have histologic or cytologic confirmation of the diagnosis of invasive adenocarcinoma of the breast.
Patients with a histologic diagnosis of adenocarcinoma of the esophagus located distal to the carina
Histologic diagnosis of melanoma
Eligible patients will have a histologic or cytologic diagnosis of NSCLC of the advanced stage (IV), with no known curative treatment options
Patients must have cytologic or histologic confirmation of carcinoma arising in the pancreas; patients with neuroendocrine tumors are excluded
All patients with histologic proof of advanced solid tumors, who are not candidates for known regimens or protocol treatments of higher efficacy or priority
No histologic documentation of breast adenocarcinoma
All patients with histologic proof of malignant melanoma. Histologic confirmation may be from the primary tumor site, or from another metastatic site (systemic lymph node, etc). Cytology-alone is not an acceptable method of diagnosis.
Histologic or cytologic confirmation of invasive breast cancer that is HER-negative by standard clinical criteria
Pathologically proven (either histologic or cytologic) diagnosis of urothelial carcinoma
Histologic confirmation of invasive adenocarcinoma originating in the breast
Patients must have histologic or cytologic diagnosis of non-melanoma skin cancer (NMSC) or lymphomas other than B-cell lymphomas; as both of those terms are categories rather than specific diagnoses, specific guidance on eligible tumor types is provided below
Diagnosis of MPM, confined to single pleural cavity, with histologic confirmation of the primary tumor
Cohort  (dose escalation): histologic or cytologic proof of any solid tumor that is incurable with no standard therapy that is likely to make a major impact on clinical outcomes
Histologic confirmation of NSCLC (if not already obtained)
Subjects with a histologic diagnosis of solid tumor cancers of epithelial origin.
Histologic or cytologic confirmation of a solid malignancy with established intolerance or refractoriness to standard therapies
Patients must have histologic proof of active AML at time of enrollment
Histologic confirmation of advanced solid tumors
Patients must have histologic or cytologic evidence of adenocarcinoma of the pancreas, such as a core tissue biopsy or a surgical resection specimen.
The diagnosis of mCRC will be based on histologic or cytologic confirmation
Clinical and definitive histologic diagnosis of WM
Histologic confirmation of malignancy (primary or metastatic tumor)
Participants must have histologically or cytologically confirmed cervical cancer which is now recurrent or metastatic and is refractory to curative therapy or established treatments; histologic or cytologic confirmation of the original primary tumor is required; all histologic types of cervical origin are permitted
Histologic or cytologic diagnosis of SCLC (Note: patients with mixed histology are not eligible)
Cytologic or histologic proof pancreatic ductal carcinoma is required prior to study entry; diagnosis must be confirmed by a Dana-Farber Harvard Cancer Center (DFHCC) institution pathology department prior to registration
Histologic or cytologic diagnosis of adenocarcinoma of the pancreas.
Cytologic or histologic proof pancreatic ductal carcinoma is required prior to study entry; diagnosis must be confirmed by the Massachusetts General Hospital (MGH) pathology department
Have a histologic or cytologic diagnosis of prostate cancer
Cytologic or histologic proof of adenocarcinoma of the pancreas is required prior to treatment; patients with Islet cell tumors are not eligible
Histologic variants in the primary tumor (histologic variants other than adenocarcinoma)
Cytologic or histologic proof of pancreatic ductal carcinoma is required prior to study entry; diagnosis must be confirmed by the Massachusetts General Hospital (MGH) pathology department prior to registration
Histologic or cytologic diagnosis of pancreas adenocarcinoma advanced or recurrent (stage III or IV) that is unresectable; histologic or cytologic pathology from any prior surgery is sufficient for diagnosis
Histologic/cytologic proof of stage IV malignant melanoma not amenable to surgery
Histologic or cytologic confirmation of thyroid cancer (papillary, follicular, medullary); histologic variants such as Hurthle and tall cell variants are allowed
Histologic diagnosis has been verified by institutional pathologist and classified according to the WHO () system
Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS.
Phase a: Have histologic or cytologic confirmation of advanced solid tumor
Histologic diagnosis of melanoma.
Histologic variants other than adenocarcinoma in the primary tumor
Predominantly squamous, adenosquamous or unclear histologic type
Histologic or cytologic confirmation of head and neck malignancy without clinical or radiographic evidence of metastatic disease
Have histologic or cytologic documentation of solid tumor including EGFR mutated (EGFRm) NSCLC
Histologic or cytologic confirmed diagnosis of small cell lung cancer, either limited or extensive disease at initial presentation is allowed
Histologic proof of presence of residual tumor in liver explants and /or positive resection margins
Patients must have histologic proof of a malignancy suitable for radiation therapy
Histologic confirmation not required if other diagnostic criteria are met;
Phase II : Diagnosis of recurrent, metastatic or primary unresectable ATC, including ATC as part of a thyroid carcinoma of another histologic subtype
Histologic or cytologic confirmation of a solid malignancy
Patients with pre-operative histologic confirmation of a bladder lesion other than transitional cell carcinoma
Any histologic subtype
All patients must have histologic proof of solid tumor malignancy and radiographic evidence of spine metastasis
Histologic diagnosis of malignancy of a solid organ or lymphoma
Pathologically (histologically or cytologically) proven diagnosis of solid tumor malignancy within  years prior to Step  registration; if the original histologic proof of malignancy is greater than  years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis)
Histologic confirmation of leukemia or myelodysplatic syndrome (MDS) at the time of diagnosis or recurrence
Patients with a histologic diagnosis of adenocarcinoma of the esophagus located distal to the carina
Patients with histologic or cytologic proof of pancreatic cancer, for whom the treatment plan, at the time of enrollment, is chemoradiation
Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC); pathologic confirmation is mandated before initiation of any protocol specified imaging studies or drug administrations; it is recognized that for some patients, histologic or cytologic confirmation of cancer may be obtained following study enrollment; patient volunteers to the DW- and DCE-MRI sequence parameter optimization imaging portion of the study are eligible if they have any pancreatic lesion, histologic or cytologic confirmation of pathology is not required for this patient volunteer group
Subject must have histologic or cytologic confirmation of advanced melanoma
Any non-adenocarcinoma histologic component
Patients with histologic or cytologic diagnosis of advanced or metastatic solid tumors or lymphomas for which no curative or life-prolonging therapies exist.
Women without histologic confirmation of nodal involvement
